CoronaryAtlas logo
CoronaryAtlas
B-cell lymphoma 6
Pathway / Plaque inflammation

B-cell lymphoma 6

BCL6protein

BCL-6 is an miR-155 target that dampens inflammatory signaling; its suppression permits plaque inflammation amplification.

Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleBCL-6 suppression by miR-155 reduces anti-inflammatory control of immune responses.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000113916

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
32
C — non-Type-I
64
A — assay feasibility
68
E — evidence strength
25
T1DI (composite)
6
Specificity differential (R−C)-32.2
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(1)